Active	Status	Sponsor type	Region	Phase	Filter
8 Active 1 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Skeel, Roland T
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC	Active, not recruiting	2	68	US, RoW	Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®	Effector Therapeutics, Medpace, Inc., ICON plc	Non-small Cell Lung Cancer	10/24	12/24
NCT05001516: Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors	Completed	1	17	US	LM-302	Turning Point Therapeutics, Inc.	Advanced Solid Tumor	01/24	01/24
NCT03819387: A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer	Completed	1	49	US	NBF-006	Nitto BioPharma, Inc.	Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer	11/23	03/24